Last checked at 21 Aug 2019 07:00
Uniphar plc
Notice of Interim Results
Dublin, London, 21 August 2019: Uniphar plc (the "Company" or the "Group"), a diversified healthcare services provider, will announce its interim results for the half year ended 30 June 2019 at 07:00 am (GMT) on Tuesday 17 September 2019.
A conference call for analysts and investors will be held at 9.00 am (GMT) on the day to discuss the Group's interim results. Analysts and investors who wish to participate should visit https://www.uniphar.ie/cms/investors to register.
The Company's half year results press release and presentation will be available on the website at 07.00 am (GMT) on 17 September 2019 at www.uniphar.ie.
--- ENDS ---
For further details contact:
Uniphar
Brian O'Shaughnessy Director of Investor Relations and Corporate Development
| +353 (0) 1 428 7777
investor.relations@Uniphar.ie
|
Davy (Joint Broker, Nominated Adviser and Euronext Growth Adviser)
Fergal Meegan Barry Murphy Tom Tynan
| +353 (0) 1 679 6363 |
RBC Capital Markets (Joint Broker) Darrell Uden Jonathan Hardy Thomas Debrosse
| +44 (0) 20 7653 4000 |
Q4 PR (Public Relations Adviser to Uniphar)
Iarla Mongey
| +353 (0) 1 475 1444 or +353 87 235 6461 |
About Uniphar plc
Headquartered in Dublin, Ireland, Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access, and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK, the Benelux and the US.
In Commercial & Clinical, the Group provides sales, marketing and distribution solutions to pharmaceutical and medical devices manufacturers on an outsourced basis.
In Product Access, the Group is growing two distinct service offerings: 1) sourcing and supplying unlicensed medicines to meet the needs of pharmacy customers (On-Demand Access); and 2) managing the release of speciality medicines for pharmaceutical manufacturers to specifically approved patient populations (Exclusive Access).
Supply Chain & Retail is an Irish only business for the Group, with Uniphar being an established market leader in Ireland with c.50% of the wholesale market servicing retail pharmacy, supported by a network of 235 owned and franchised pharmacies.